Susan Tsai
YOU?
Author Swipe
View article: Processing properties of cell-wall disrupted macroalgae in plant-based meat and the concept of a sustainable algal modifier database
Processing properties of cell-wall disrupted macroalgae in plant-based meat and the concept of a sustainable algal modifier database Open
View article: Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma Open
Therapies targeting the RAF-MEK-ERK pathway are generally considered to have limited efficacy in KRAS mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumo…
View article: Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma
Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma Open
View article: Association of Hospital Flagship System Affiliation on Surgical Outcomes Following Complex Cancer Surgery
Association of Hospital Flagship System Affiliation on Surgical Outcomes Following Complex Cancer Surgery Open
Background: We evaluated variations in patient outcomes and financial expenditures following complex cancer surgery across flagship hospitals and their affiliates. Methods: Using Medicare 100% Standard Analytic Files (2018–2021), we identi…
View article: AI-Derived Electronic Tumor Marker (e19-9) Can Measure Treatment Response and Outcomes in CA19-9 Non-Producers with Pancreatic Ductal Adenocarcinoma
AI-Derived Electronic Tumor Marker (e19-9) Can Measure Treatment Response and Outcomes in CA19-9 Non-Producers with Pancreatic Ductal Adenocarcinoma Open
Background Clinicians use Cancer Antigen 19 − 9 (CA19-9) to assess treatment response and inform clinical decisions for patients with pancreatic ductal adenocarcinoma (PDAC). However, nearly 30% of patients with PDAC do not have an elevate…
View article: Biotransformation of Key Compounds and Antioxidant Capacity in Lemon By-Products via Multi-Strain Fermentation
Biotransformation of Key Compounds and Antioxidant Capacity in Lemon By-Products via Multi-Strain Fermentation Open
View article: Association of county‐level provider density with hepatobiliary cancer incidence and mortality
Association of county‐level provider density with hepatobiliary cancer incidence and mortality Open
Background Access to healthcare providers is a key factor in reducing cancer incidence and mortality, underscoring the significance of provider density as a crucial metric of health quality. We sought to characterize the association of pro…
View article: Long-term Health Outcomes of New Persistent Opioid Use After Gastrointestinal Cancer Surgery
Long-term Health Outcomes of New Persistent Opioid Use After Gastrointestinal Cancer Surgery Open
Background New persistent opioid use (NPOU) after surgery has been identified as a common complication. This study sought to assess the long-term health outcomes among patients who experienced NPOU after gastrointestinal (GI) cancer surger…
View article: ASO Visual Abstract: Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery
ASO Visual Abstract: Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery Open
View article: Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery
Association of Hospital Market Competition with Outcomes of Complex Cancer Surgery Open
View article: Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival
Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival Open
BACKGROUND Pancreatic cancer is a leading cause of cancer-related deaths. Increased activity of the epidermal growth factor receptor (EGFR) is often observed in pancreatic cancer, and the small molecule EGFR inhibitor erlotinib has been ap…
View article: MEK Inhibitor Therapy in Pancreatic Ductal Adenocarcinoma with KRAS G12R Mutation
MEK Inhibitor Therapy in Pancreatic Ductal Adenocarcinoma with KRAS G12R Mutation Open
View article: Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series Open
Background: KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in a real-world setting, to date, is less establ…
View article: Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy Open
Purpose/Objectives Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify clinical characteristics associated with prolonged overall survival (OS) in patients pr…
View article: Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer
Single-cell mapping identifies MSI+ cells as a common origin for diverse subtypes of pancreatic cancer Open
View article: Patterns of Locoregional Pancreatic Cancer Recurrence after Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes
Patterns of Locoregional Pancreatic Cancer Recurrence after Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes Open
View article: Automated machine learning (AutoML) can predict 90-day mortality after gastrectomy for cancer
Automated machine learning (AutoML) can predict 90-day mortality after gastrectomy for cancer Open
Early postoperative mortality risk prediction is crucial for clinical management of gastric cancer. This study aims to predict 90-day mortality in gastric cancer patients undergoing gastrectomy using automated machine learning (AutoML), op…
View article: Supplementary figure legends from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Supplementary figure legends from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Supplementary figure legends
View article: Figure S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
In vitro molecular characterization of mAb inhibition of CLPTM1L signaling
View article: Figure S6 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S6 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Inhibition of MiaPaca tumorigenesis with purified anti-CLPTM1L and animal weight data
View article: Figure S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Monoclonal antibody epitope selection
View article: Table S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Table S3 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
In vitro characterization of monoclonal anti-CLPTM1L antibodies
View article: Data from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Data from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
We and others have recently shown cisplatin resistance-related protein 9 (CRR9)/Cleft Lip and Palate Transmembrane 1-Like (CLPTM1L) to affect survival and proliferation in lung and pancreatic tumor cells. Our research has indicated that CL…
View article: Table S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Table S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Clinical characteristics of CLPTM1L expression and survival study subjects
View article: Table S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Table S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Selected epitopes for monoclonal antibody development
View article: Figure S4 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S4 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Inhibition of colony formation in select human cancer cell lines with anti-CLPTM1L
View article: Figure S4 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S4 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Inhibition of colony formation in select human cancer cell lines with anti-CLPTM1L
View article: Table S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Table S2 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Selected epitopes for monoclonal antibody development
View article: Table S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Table S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
Clinical characteristics of CLPTM1L expression and survival study subjects
View article: Figure S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling
Figure S1 from Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling Open
CLPTM1L structural prediction